BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...in blood cancer.Merck & Co. Inc. (NYSE:MRK) will gain rights to VLS-101, an ADC targeting ROR1...
...ADCs targeting ROR1.Merck spokesperson Pamela Eisele told BioCentury the deal represents Merck’s entry into the ROR1...
...Price, Venrock, Viking Global Investors and Wellington Management Co.TARGETSROR1 - Receptor tyrosine kinase-like orphan receptor 1 Paul Bonanos Merck & Co. Inc. VelosBio Inc. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) chs2020...
BioCentury | Oct 31, 2020
Distillery Therapeutics

Blocking ROR2 for osteoarthritis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoarthritis Inhibiting the tyrosine protein kinase receptor ROR2 could treat osteoarthritis. Expression levels of the ROR2 ligand WNT5A were higher in human osteoarthritic cartilage than in healthy cartilage. In a mouse fibroblast...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...Ltd. (HKEX:2616) licensed exclusive rights outside of South Korea for a preclinical antibody-drug conjugate targeting ROR1...
...million in milestones plus tiered royalties for rights to LCB71. There are no ADCs targeting ROR1...
...Asabys Partners with participation by existing investors Novator and Frumtak Ventures.TARGETSIL-7R - Interleukin-7 receptorROR1Receptor tyrosine kinase-like orphan receptor 1 BC...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

...told BioCentury. VelosBio intends to advance clinical development of lead antibody-drug conjugate VLS-101, which targets ROR1...
...should also enable VelosBio to bring a next-generation ADC and a bispecific antibody, both against ROR1...
...of $202 million since its 2017 launch (see “ Fruitful Partnerships” ). Targets ROR1 - Receptor tyrosine kinase-like orphan receptor 1 Virginia...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

...subfamily K member 1 (NKG2D) (KLRK1) (CD314) Prostate stem cell antigen (PSCA) Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Receptor tyrosine kinase-like orphan receptor 1 (ROR1) CAR...
BioCentury | Apr 11, 2019
Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

...details. WuXi Biologics Inc. (HKSE:2269) did not respond to inquiries. NBE-002 is an antibody against receptor tyrosine kinase-like orphan receptor 1 (ROR1)...
...TNBC), lung cancer, chronic lymphocytic leukemia and mantle cell lymphoma. Hongjiang Li, Staff Writer NBE-002 NBE-Therapeutics AG WuXi Biologics Inc. Receptor tyrosine kinase-like orphan receptor 1 (ROR1)...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

...lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1)...
..."GTX Shares Crater After Incontinence Readout" ). Shannon Lehnbeuter, Staff Writer Cirmtuzumab (UC-961) Selective androgen receptor degrader (SARD) TK216, TK-216 Receptor tyrosine kinase-like orphan receptor 1 (ROR1)...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BioCentury | Dec 7, 2018
Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
BioCentury | May 23, 2018
Distillery Therapeutics

Cancer

...pretreatment with the nanoparticles for three weeks followed by treatment with CAR T cells targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)...
Items per page:
1 - 10 of 43